Corleen M. Roche

CIK: 0001857905

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (14.3%)

Derivative conversions

Awards (A)5 (71.4%)

Compensation grants

Other (G, F, J, C, D, …)1 (14.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

IOVA

IOVANCE BIOTHERAPEUTICS, INC.

Officer

CGON

CG Oncology, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Aug 6, 2026
Exercise(M)
Direct
50K shares-
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Aug 6, 2026
Tax Payment(F)
Direct
21.2K shares at avg. $6.21$132K
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Mar 9, 2026
Award(A)
Restricted Stock Units
Direct
132.2K shares-
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Aug 6, 2025
Award(A)
Restricted Stock Units
Direct
150K shares-
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Aug 6, 2025
Award(A)
Stock Option (right to buy)
Direct
300K shares-
CGON
CG Oncology, Inc.
Apr 15, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
143.9K shares-
CGON
CG Oncology, Inc.
Oct 4, 2024
Award(A)
Stock Option (Right to Buy)
Direct
93.6K shares-

		Type	Shares	Price		Ownership
Aug 6, 2026	IOVA IOVANCE BIOTHERAPEUTICS, INC.	Exercise(M)	49,995	-	$0	Direct
Aug 6, 2026	IOVA IOVANCE BIOTHERAPEUTICS, INC.	Tax Payment(F)	21,238	$6.21	$131,888	Direct
Mar 9, 2026	IOVA IOVANCE BIOTHERAPEUTICS, INC.	Award(A) Restricted Stock Units	132,200	-	-	Direct
Aug 6, 2025	IOVA IOVANCE BIOTHERAPEUTICS, INC.	Award(A) Restricted Stock Units	150,000	-	-	Direct
Aug 6, 2025	IOVA IOVANCE BIOTHERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	300,000	-	-	Direct
Apr 15, 2025	CGON CG Oncology, Inc.	Award(A) Employee Stock Option (Right to Buy)	143,907	-	-	Direct
Oct 4, 2024	CGON CG Oncology, Inc.	Award(A) Stock Option (Right to Buy)	93,600	-	-	Direct

1-7 of 7 transactions

About Roche Corleen M.

Roche Corleen M. (SEC CIK 0001857905) files insider reports with the SEC as Chief Financial Officer of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and CFO of CG Oncology, Inc. (CGON).

Signal8 holds 6 ownership filings by Roche Corleen M. (1 Form 3, 5 Form 4), filed between Oct 8, 2024 and Aug 10, 2026. Those filings report 7 transactions, from Oct 4, 2024 to Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Roche Corleen M.'s filings is in SAN CARLOS, CA.

Recent filings by Roche Corleen M.

Aug 6, 2026: Option exercise of IOVA shares (Form 4, code M).
Aug 6, 2026: Tax withholding of IOVA shares (Form 4, code F).
Mar 9, 2026: Grant or award of IOVA derivative securities (Form 4, code A).
Aug 6, 2025: Grants or awards of IOVA derivative securities (2 lines, Form 4, code A).
Apr 15, 2025: Grant or award of CGON derivative securities (Form 4, code A).

Other insiders filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Berkowitz Noah, Chief Medical Officer
Vogt Frederick G, Interim CEO & General Counsel
BILINSKY IGOR, Chief Operating Officer
Puri Raj K., Chief Regulatory Officer
Kirby Daniel Gordon, Chief Commercial Officer
WEISER MICHAEL, Director

How to read Form 4 transaction codes